Biomarker-guided therapy for colorectal cancer: strength in complexity
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarker-guided therapy for colorectal cancer: strength in complexity
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-09
DOI
10.1038/s41571-019-0241-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Context Matters - Consensus Molecular Subtypes of Colorectal Cancer as Biomarkers for Clinical Trials
- (2019) E Fontana et al. ANNALS OF ONCOLOGY
- A Clinically Applicable Gene-Expression Classifier Reveals Intrinsic and Extrinsic Contributions to Consensus Molecular Subtypes in Primary and Metastatic Colon Cancer
- (2019) Robert Piskol et al. CLINICAL CANCER RESEARCH
- Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
- (2019) Heinz-Josef Lenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
- (2019) Cathy Eng et al. LANCET ONCOLOGY
- CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer
- (2018) J Smeby et al. ANNALS OF ONCOLOGY
- Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
- (2018) S Siena et al. ANNALS OF ONCOLOGY
- RET fusions in a small subset of advanced colorectal cancers at risk of being neglected
- (2018) F Pietrantonio et al. ANNALS OF ONCOLOGY
- RET-fusions: a novel paradigm in colorectal cancer
- (2018) C Santos et al. ANNALS OF ONCOLOGY
- RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases
- (2018) Masayuki Okuno et al. ANNALS OF SURGICAL ONCOLOGY
- Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
- (2018) Jeffrey S. Ross et al. CANCER
- Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer
- (2018) Giulia Siravegna et al. CANCER CELL
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- (2018) Rona Yaeger et al. CANCER CELL
- Consensus molecular subtypes of colorectal cancer are recapitulated in in vitro and in vivo models
- (2018) Janneke F. Linnekamp et al. CELL DEATH AND DIFFERENTIATION
- Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies
- (2018) Rodrigo A. Toledo et al. CLINICAL CANCER RESEARCH
- Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical significance of BRAF non-V600E mutations in colorectal cancer: a retrospective study of two institutions
- (2018) Yoshifumi Shimada et al. JOURNAL OF SURGICAL RESEARCH
- Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
- (2018) Jonathan M Loree et al. JNCI-Journal of the National Cancer Institute
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Prognostic, predictive and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
- (2018) Jarle Bruun et al. Molecular Oncology
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- (2018) Axel Grothey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome of Mismatch Repair‐Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience
- (2018) Zhaohui Jin et al. ONCOLOGIST
- Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
- (2018) Yan Lan et al. Science Translational Medicine
- Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAF V600E Colorectal Cancer
- (2018) Mehlika Hazar-Rethinam et al. Cancer Discovery
- Genetic Mechanisms of Immune Evasion in Colorectal Cancer
- (2018) Catherine S. Grasso et al. Cancer Discovery
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- Molecular Landscape of ERBB2/ERBB3 Mutated Colorectal Cancer
- (2018) Jonathan M Loree et al. JNCI-Journal of the National Cancer Institute
- Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors
- (2018) Rebekka Weber et al. Frontiers in Immunology
- PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer
- (2018) Magalie Dosset et al. OncoImmunology
- Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer
- (2018) Guoying Zhou et al. OncoImmunology
- Estimation of The Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology
- (2018) John Marquart et al. JAMA Oncology
- Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.
- (2018) Yucai Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?
- (2018) Marta Schirripa et al. JOURNAL OF CLINICAL ONCOLOGY
- A validation study of stratification by the 55-gene classifier for assessing recurrence risk in stage II colon cancer: The 55 STAR study (UMIN23879).
- (2018) Shigeki Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).
- (2018) Volker Heinemann et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.
- (2018) Alice Tsang Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- HER kinase inhibition in patients with HER2- and HER3-mutant cancers
- (2018) David M. Hyman et al. NATURE
- BRAF V600E Mutation as a Negative Prognostic Determinant in Resected Colorectal Liver Metastases—Reply
- (2018) Georgios Antonios Margonis et al. JAMA Surgery
- 12PMSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies
- (2018) J Galon et al. ANNALS OF ONCOLOGY
- LBA19Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
- (2018) A Grothey et al. ANNALS OF ONCOLOGY
- LBA20TRIBE2: A phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)
- (2018) C Cremolini et al. ANNALS OF ONCOLOGY
- 457PDKinase fusions in colorectal cancers: A unique biologic subset
- (2018) R Madison et al. ANNALS OF ONCOLOGY
- Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
- (2018) T A Chan et al. ANNALS OF ONCOLOGY
- Fusion Kinases Identified by Genomic Analyses of Sporadic Microsatellite Instability–High Colorectal Cancers
- (2018) Kazuhito Sato et al. CLINICAL CANCER RESEARCH
- Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
- (2018) Marcel Wiesweg et al. ONCOGENE
- Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency
- (2017) R. Cohen et al. EUROPEAN JOURNAL OF CANCER
- The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials
- (2017) Julian Walter Holch et al. EUROPEAN JOURNAL OF CANCER
- CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
- (2017) Hege Marie Vedeld et al. INTERNATIONAL JOURNAL OF CANCER
- Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
- (2017) Howard S. Hochster et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG 1406).
- (2017) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology
- (2017) Antonia R. Sepulveda et al. JOURNAL OF CLINICAL ONCOLOGY
- Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
- (2017) Jeremy C. Jones et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
- (2017) Katrin M Sjoquist et al. JNCI-Journal of the National Cancer Institute
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
- (2017) Filippo Pietrantonio et al. JNCI-Journal of the National Cancer Institute
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring aPOLEMutation
- (2017) Jun Gong et al. Journal of the National Comprehensive Cancer Network
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insights
- (2017) Rodrigo Dienstmann et al. Molecular Oncology
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection
- (2017) Guillaume Passot et al. SURGERY
- Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification
- (2017) Philip D. Dunne et al. Nature Communications
- Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors
- (2017) Moritz Schütte et al. Nature Communications
- Selective analysis of cancer-cell intrinsic transcriptional traits defines novel clinically relevant subtypes of colorectal cancer
- (2017) Claudio Isella et al. Nature Communications
- A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer
- (2017) Robin M.J.M. van Geel et al. Cancer Discovery
- Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer
- (2017) Jesper Bertram Bramsen et al. Cell Reports
- Multilevel genomics of colorectal cancers with microsatellite instability—clinical impact of JAK1 mutations and consensus molecular subtype 1
- (2017) Anita Sveen et al. Genome Medicine
- Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
- (2017) Katrin M Sjoquist et al. JNCI-Journal of the National Cancer Institute
- ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
- (2017) Filippo Pietrantonio et al. JNCI-Journal of the National Cancer Institute
- Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival
- (2017) Bernhard Mlecnik et al. JNCI-Journal of the National Cancer Institute
- A Blueprint to Advance Colorectal Cancer Immunotherapies
- (2017) Dung T. Le et al. Cancer Immunology Research
- POLE somatic mutations in advanced colorectal cancer
- (2017) Joana Guerra et al. Cancer Medicine
- Neoadjuvant chemotherapy affects molecular classification of colorectal tumors
- (2017) K Trumpi et al. Oncogenesis
- Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers
- (2017) Frank A. Sinicrope et al. JAMA Oncology
- Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3—A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.
- (2017) Sebastian Stintzing et al. JOURNAL OF CLINICAL ONCOLOGY
- RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
- (2017) Kristoffer W. Brudvik et al. ANNALS OF SURGERY
- Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
- (2016) D. P. Modest et al. ANNALS OF ONCOLOGY
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
- (2016) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers
- (2016) Chang Gon Kim et al. BRITISH JOURNAL OF CANCER
- Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching
- (2016) Linde De Smedt et al. BRITISH JOURNAL OF CANCER
- Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases
- (2016) Georgios A. Margonis et al. CANCER
- A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility
- (2016) Loredana Vecchione et al. CELL
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer
- (2016) Matthew G. Summers et al. CLINICAL CANCER RESEARCH
- BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
- (2016) David Barras et al. CLINICAL CANCER RESEARCH
- Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target
- (2016) E. Yakirevich et al. CLINICAL CANCER RESEARCH
- Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
- (2016) Etienne Becht et al. CLINICAL CANCER RESEARCH
- Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer
- (2016) Filippo Pietrantonio et al. CLINICAL CANCER RESEARCH
- Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry
- (2016) Anne Trinh et al. CLINICAL CANCER RESEARCH
- Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses
- (2016) Sigurdis Haraldsdottir et al. GENETICS IN MEDICINE
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
- (2016) Bernhard Mlecnik et al. IMMUNITY
- Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients
- (2016) Amos Kirilovsky et al. INTERNATIONAL IMMUNOLOGY
- HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
- (2016) Susan D Richman et al. JOURNAL OF PATHOLOGY
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
- (2016) David Tougeron et al. JNCI-Journal of the National Cancer Institute
- Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer
- (2016) Aparna Parikh et al. Journal of the National Comprehensive Cancer Network
- Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
- (2016) Grazia Palomba et al. Journal of Translational Medicine
- Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
- (2016) Andrea Sartore-Bianchi et al. LANCET ONCOLOGY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
- (2016) Piero Dalerba et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer
- (2016) F. Pietrantonio et al. Cancer Discovery
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
- (2016) D. S. Hong et al. Cancer Discovery
- Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
- (2016) M. P. Patricelli et al. Cancer Discovery
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
- (2016) Marios Giannakis et al. Cell Reports
- Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
- (2016) Julien Taieb et al. JNCI-Journal of the National Cancer Institute
- Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study
- (2016) David Tougeron et al. JNCI-Journal of the National Cancer Institute
- Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes
- (2016) Nan Song et al. JAMA Oncology
- Prognostic Effect ofBRAFandKRASMutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab
- (2016) Julien Taieb et al. JAMA Oncology
- LBA-07Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
- (2015) E. Van Cutsem et al. ANNALS OF ONCOLOGY
- BRAFcodons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
- (2015) C. Cremolini et al. ANNALS OF ONCOLOGY
- Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment
- (2015) M. P. Morelli et al. ANNALS OF ONCOLOGY
- Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
- (2015) Beatrix Bencsikova et al. BMC GASTROENTEROLOGY
- Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer
- (2015) Alessio Amatu et al. BRITISH JOURNAL OF CANCER
- KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
- (2015) S Renaud et al. BRITISH JOURNAL OF CANCER
- Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
- (2015) A Rowland et al. BRITISH JOURNAL OF CANCER
- Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer
- (2015) T T Seppälä et al. BRITISH JOURNAL OF CANCER
- BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
- (2015) M Schirripa et al. BRITISH JOURNAL OF CANCER
- Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
- (2015) J. F. Linnekamp et al. CANCER RESEARCH
- Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
- (2015) Marc van de Wetering et al. CELL
- Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance)
- (2015) F. A. Sinicrope et al. CLINICAL CANCER RESEARCH
- Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients
- (2015) R. Yaeger et al. CLINICAL CANCER RESEARCH
- Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983
- (2015) Erik Tanis et al. EUROPEAN JOURNAL OF CANCER
- Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
- (2015) Filippo Pietrantonio et al. EUROPEAN JOURNAL OF CANCER
- Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes
- (2015) Frank A. Sinicrope et al. GASTROENTEROLOGY
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600–Mutant Colorectal Cancer
- (2015) Ryan B. Corcoran et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients
- (2015) Rodrigo Dienstmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer
- (2015) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
- (2015) Chiara Cremolini et al. LANCET ONCOLOGY
- Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
- (2015) Josep Tabernero et al. LANCET ONCOLOGY
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation study
- (2015) Emanuele Valtorta et al. MODERN PATHOLOGY
- Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer
- (2015) Martin P Barr et al. Molecular Cancer
- The genomic landscape of response to EGFR blockade in colorectal cancer
- (2015) Andrea Bertotti et al. NATURE
- Targeting PTPRK-RSPO3 colon tumours promotes differentiation and loss of stem-cell function
- (2015) Elaine E. Storm et al. NATURE
- Stromal gene expression defines poor-prognosis subtypes in colorectal cancer
- (2015) Alexandre Calon et al. NATURE GENETICS
- Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
- (2015) Giulia Siravegna et al. NATURE MEDICINE
- The consensus molecular subtypes of colorectal cancer
- (2015) Justin Guinney et al. NATURE MEDICINE
- First-line chemotherapy for mCRC—a review and evidence-based algorithm
- (2015) Chiara Cremolini et al. Nature Reviews Clinical Oncology
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Wnt addiction of genetically defined cancers reversed by PORCN inhibition
- (2015) B Madan et al. ONCOGENE
- Prognostic value ofKRASandBRAFmutations in curatively resected colorectal cancer
- (2015) Shigenori Kadowaki WORLD JOURNAL OF GASTROENTEROLOGY
- The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets
- (2015) Enzo Medico et al. Nature Communications
- Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer
- (2015) M. Russo et al. Cancer Discovery
- HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment
- (2015) S. M. Kavuri et al. Cancer Discovery
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
- (2015) Mihaela Angelova et al. GENOME BIOLOGY
- Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
- (2015) Andrea Sartore-Bianchi et al. JNCI-Journal of the National Cancer Institute
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
- (2015) Fotios Loupakis et al. JNCI-Journal of the National Cancer Institute
- Pharmacologic resistance in colorectal cancer: a review
- (2015) William A. Hammond et al. Therapeutic Advances in Medical Oncology
- High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
- (2015) Halfdan Sorbye et al. PLoS One
- ExtendedRASmutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials
- (2014) M. J. Sorich et al. ANNALS OF ONCOLOGY
- Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial
- (2014) D. Klingbiel et al. ANNALS OF ONCOLOGY
- Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset
- (2014) H. Blons et al. ANNALS OF ONCOLOGY
- BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer
- (2014) Rona Yaeger et al. CANCER
- Immune Escape and Survival Mechanisms in Circulating Tumor Cells of Colorectal Cancer
- (2014) Gunnar Steinert et al. CANCER RESEARCH
- Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
- (2014) S. Venderbosch et al. CLINICAL CANCER RESEARCH
- Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer
- (2014) Van Morris et al. Clinical Colorectal Cancer
- The R-spondin/Lgr5/Rnf43 module: regulator of Wnt signal strength
- (2014) W. de Lau et al. GENES & DEVELOPMENT
- Role ofNRASmutations as prognostic and predictive markers in metastatic colorectal cancer
- (2014) Marta Schirripa et al. INTERNATIONAL JOURNAL OF CANCER
- The prognostic role of microsatellite instability, codon-specificKRAS, andBRAFmutations in colon cancer
- (2014) Chun-Chi Lin et al. JOURNAL OF SURGICAL ONCOLOGY
- Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147
- (2014) Wilson I. Gonsalves et al. JNCI-Journal of the National Cancer Institute
- RSPO fusion transcripts in colorectal cancer in Japanese population
- (2014) Kazuya Shinmura et al. MOLECULAR BIOLOGY REPORTS
- A very low incidence of BRAF mutations in Middle Eastern colorectal carcinoma
- (2014) Abdul K Siraj et al. Molecular Cancer
- Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
- (2014) Yu Imamura et al. Molecular Cancer
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- RNF43 is frequently mutated in colorectal and endometrial cancers
- (2014) Marios Giannakis et al. NATURE GENETICS
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Can we safely target the WNT pathway?
- (2014) Michael Kahn NATURE REVIEWS DRUG DISCOVERY
- Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations
- (2014) TOSHIRO OGURA et al. ONCOLOGY REPORTS
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- The landscape of kinase fusions in cancer
- (2014) Nicolas Stransky et al. Nature Communications
- The Vigorous Immune Microenvironment of Microsatellite Instable Colon Cancer Is Balanced by Multiple Counter-Inhibitory Checkpoints
- (2014) Nicolas J. Llosa et al. Cancer Discovery
- Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing
- (2014) Sumitra Mohan et al. PLoS Genetics
- Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations
- (2013) Dmitri Mouradov et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) R. Labianca et al. ANNALS OF ONCOLOGY
- Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer
- (2013) Vlad Popovici et al. BMC CANCER
- EMT is the dominant program in human colon cancer
- (2013) Andre Loboda et al. BMC Medical Genomics
- KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
- (2013) A I Phipps et al. BRITISH JOURNAL OF CANCER
- The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
- (2013) V Eklöf et al. BRITISH JOURNAL OF CANCER
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
- (2013) V Martin et al. BRITISH JOURNAL OF CANCER
- A Genetic Progression Model of BrafV600E-Induced Intestinal Tumorigenesis Reveals Targets for Therapeutic Intervention
- (2013) Roland Rad et al. CANCER CELL
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
- (2013) M. Peeters et al. CLINICAL CANCER RESEARCH
- PIK3CA, BRAF , and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17
- (2013) Christos S. Karapetis et al. CLINICAL CANCER RESEARCH
- Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy Cetuximab
- (2013) C. G. Smith et al. CLINICAL CANCER RESEARCH
- KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib
- (2013) John C. Smith et al. EUROPEAN JOURNAL OF CANCER
- FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
- (2013) F. Loupakis et al. EUROPEAN JOURNAL OF CANCER
- Associations Between Colorectal Cancer Molecular Markers and Pathways With Clinicopathologic Features in Older Women
- (2013) N.Jewel Samadder et al. GASTROENTEROLOGY
- Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update
- (2013) M.J. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition
- (2013) Paul Roepman et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy
- (2013) Frank A. Sinicrope et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer
- (2013) Eva Budinska et al. JOURNAL OF PATHOLOGY
- BRAF Mutation and Microsatellite Instability Status in Colonic and Rectal Carcinoma: Context Really Does Matter
- (2013) S. R. Hamilton JNCI-Journal of the National Cancer Institute
- Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
- (2013) Paul Lochhead et al. JNCI-Journal of the National Cancer Institute
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial
- (2013) Bernard Nordlinger et al. LANCET ONCOLOGY
- Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
- (2013) Matthew T Seymour et al. LANCET ONCOLOGY
- Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions
- (2013) Felipe De Sousa E Melo et al. NATURE MEDICINE
- A colorectal cancer classification system that associates cellular phenotype and responses to therapy
- (2013) Anguraj Sadanandam et al. NATURE MEDICINE
- Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
- (2013) Jean-Yves Douillard et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRAFV600E Mutation Analysis in Patients with Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice: Correlations with Clinical Characteristics, and Its Impact on Patients’ Outcome
- (2013) Zacharenia Saridaki et al. PLoS One
- Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value
- (2013) Laetitia Marisa et al. PLOS MEDICINE
- Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study
- (2013) Sakarias Wangefjord et al. Biology of Sex Differences
- Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration
- (2013) Niels Halama et al. OncoImmunology
- Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series
- (2012) M. A. Merok et al. ANNALS OF ONCOLOGY
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
- (2012) H. J. Schmoll et al. ANNALS OF ONCOLOGY
- Colon cancer molecular subtypes identified by expression profiling and associatedto stroma, mucinous type and different clinical behavior
- (2012) Beatriz Perez Villamil et al. BMC CANCER
- Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines
- (2012) Andreas Schlicker et al. BMC Medical Genomics
- Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
- (2012) P. G. Gavin et al. CLINICAL CANCER RESEARCH
- Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
- (2012) M. Mao et al. CLINICAL CANCER RESEARCH
- Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
- (2012) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- A combined oncogenic pathway signature ofBRAF,KRASandPI3KCAmutation improves colorectal cancer classification and cetuximab treatment prediction
- (2012) Sun Tian et al. GUT
- Identification of a Poor-PrognosisBRAF-Mutant–Like Population of Patients With Colon Cancer
- (2012) Vlad Popovici et al. JOURNAL OF CLINICAL ONCOLOGY
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated Analysis of Molecular and Clinical Prognostic Factors in Stage II/III Colon Cancer
- (2012) A. D. Roth et al. JNCI-Journal of the National Cancer Institute
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
- (2012) Sandra Misale et al. NATURE
- Recurrent R-spondin fusions in colon cancer
- (2012) Somasekar Seshagiri et al. NATURE
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Molecular Genetics of Colorectal Cancer
- (2011) Eric R. Fearon Annual Review of Pathology-Mechanisms of Disease
- Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
- (2011) Ben Tran et al. CANCER
- Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy
- (2011) N. Halama et al. CANCER RESEARCH
- Defective Mismatch Repair Status as a Prognostic Biomarker of Disease-Free Survival in Stage III Colon Cancer Patients Treated with Adjuvant FOLFOX Chemotherapy
- (2011) A. Zaanan et al. CLINICAL CANCER RESEARCH
- Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
- (2011) Gordon Hutchins et al. JOURNAL OF CLINICAL ONCOLOGY
- Peritoneal carcinomatosis of colon cancer origin: Highest incidence in women and in patients with right-sided tumors
- (2011) Ole Helmer Sjo et al. JOURNAL OF SURGICAL ONCOLOGY
- DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy
- (2011) F. A. Sinicrope et al. JNCI-Journal of the National Cancer Institute
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data
- (2010) Cecilia Guastadisegni et al. EUROPEAN JOURNAL OF CANCER
- Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation
- (2010) Jeanne Tie et al. INTERNATIONAL JOURNAL OF CANCER
- Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer
- (2010) Daniel J. Sargent et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
- (2010) Wendy De Roock et al. LANCET ONCOLOGY
- Microsatellite instability in colorectal cancer—the stable evidence
- (2010) Eduardo Vilar et al. Nature Reviews Clinical Oncology
- A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)
- (2009) M. Ychou et al. ANNALS OF ONCOLOGY
- KRAS Mutation and Microsatellite Instability: Two Genetic Markers of Early Tumor Development That Influence the Prognosis of Colorectal Cancer
- (2009) Garrett M. Nash et al. ANNALS OF SURGICAL ONCOLOGY
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
- (2009) F Loupakis et al. BRITISH JOURNAL OF CANCER
- Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
- (2009) M Koopman et al. BRITISH JOURNAL OF CANCER
- Microsatellite instability and survival in rectal cancer
- (2009) Wade S. Samowitz et al. CANCER CAUSES & CONTROL
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803
- (2009) S. Ogino et al. CLINICAL CANCER RESEARCH
- KRASandBRAFMutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
- (2009) Susan D. Richman et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803
- (2009) Monica M. Bertagnolli et al. JOURNAL OF CLINICAL ONCOLOGY
- In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
- (2009) Franck Pagès et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
- (2009) Arnaud D. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- BRAFMutation in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases
- (2008) L. Barault et al. CANCER RESEARCH
- The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status
- (2008) Rodrigo Jover et al. EUROPEAN JOURNAL OF CANCER
- Genomic and Epigenetic Instability in Colorectal Cancer Pathogenesis
- (2008) William M. Grady et al. GASTROENTEROLOGY
- Wild-TypeBRAFIs Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
- (2008) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search